Mounjaro Tirzepatide 2.5mg
Mounjaro Tirzepatide 2.5mg
Ships From 🇨🇳 China, 12-15 Business Days.
Note: Separate shipping fee per warehouse.
Mounjaro® (Tirzepatide) 2.5 mg is a prescription medication containing tirzepatide, a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. Developed by Eli Lilly and Company, Mounjaro is indicated for improving glycemic control in adults with type 2 diabetes mellitus and, in some regions, may also have additional approved indications depending on local regulatory authorities.
The 2.5 mg strength is the recommended starting dose for treatment initiation. It is designed to help patients begin therapy while allowing gradual dose escalation as directed by a qualified healthcare provider.
Each carton contains 4 prefilled single-dose injection pens, providing a four-week supply when administered once weekly as directed.
Benefits
- Dual GIP and GLP-1 receptor agonist
- Once-weekly subcutaneous administration
- Initial starting dose for treatment initiation
- Supports blood glucose management in adults with type 2 diabetes (as approved)
- Convenient carton containing 4 prefilled single-dose injection pens
- Manufactured to strict pharmaceutical quality standards
Common Clinical Use
- Type 2 diabetes mellitus management
- Initial dose prior to dose escalation
- Physician-supervised metabolic therapy
Product Specifications
| Specification | Details |
|---|---|
| Product Name | Mounjaro® (Tirzepatide) |
| Strength | 2.5 mg/0.5 mL |
| Packaging | 4 Prefilled Single-Dose Injection Pens |
| Dosage Form | Solution for Injection |
| Route of Administration | Subcutaneous Injection |
| Active Ingredient | Tirzepatide |
| Manufacturer | Eli Lilly and Company |
Storage
Store refrigerated at 2°C–8°C. Do not freeze. Keep the pens in their original carton to protect them from light. Follow the manufacturer's recommendations regarding room-temperature storage before use.
Important Information
Prescription medicine.
Mounjaro must be used only under the supervision of a qualified healthcare professional and in accordance with the approved prescribing information in your country. Read the accompanying patient information leaflet before use. Keep out of reach of children.